Press

Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder

Aug 4 • 3 min read

Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it has initiated dosing in Cohort 6, the final cohort of its Phase 2 study evaluating CYB003, an investigational deuterated analog of psilocybin for the potential treatment of major depressive…

MindMed Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 4 • 6 min read

Mind Medicine Inc. (NASDAQ: MNMD / NEO: MMED), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended June 30, 2023. “We’re coming up on a critical period for MindMed as we are close to wrapping up enrollment in our Phase 2b…

Cybin Announces Closing of Overnight Marketed Public Offering of Units

Aug 4 • 3 min read

Cybin Inc. (NYSE American:CYBN / NEO:CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has closed its previously announced overnight marketed public offering (the “Offering”). In connection with the Offering, the Company issued an aggregate of 24,264,706 units of the…

MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120

Aug 4 • 4 min read

Mind Medicine (MindMed) Inc (NASDAQ: MNMD / NEO: MMED), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access Catalent’s proprietary Zydis® orally disintegrating…

FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink

Aug 4 • 4 min read

FSD Pharma Inc. (NASDAQ:HUGE / CSE:HUGE / FRA:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, is pleased to announce that it has executed a definitive agreement, signed July 31, 2023, with Celly Nutrition Inc. to grant exclusive rights to…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435